Bartlett J. Witherspoon

Radiation Oncology

515 22nd Ave
Monroe, WI 53566

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen.

Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen.

Journal: Cancer treatment and research

Published: November 30, 2022

Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update.

Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update.

Journal: Cancer treatment and research

Published: November 30, 2022

Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years.

Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years.

Journal: Cancer treatment and research

Published: November 30, 2022

Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions.

Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions.

Journal: Cancer treatment and research

Published: November 30, 2022

Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).

Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).

Journal: EClinicalMedicine

Published: August 06, 2020

Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et al.

Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et al.

Journal: Expert opinion on drug safety

Published: May 05, 2020

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.

Journal: The Lancet. Oncology

Published: April 22, 2020

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

Journal: PloS one

Published: November 27, 2019

End of an era for erythropoiesis-stimulating agents in oncology.

End of an era for erythropoiesis-stimulating agents in oncology.

Journal: International journal of cancer

Published: November 11, 2019

An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.

Journal: Expert opinion on drug safety

Published: September 11, 2019

Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.

Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.

Journal: PloS one

Published: March 18, 2019

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Journal: The oncologist

Published: June 13, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026